SOFTBANK
7.7.2021 12:32:13 CEST | Business Wire | Press release
SoftBank Group Corp. (“SBG”) today announced that Mark Kornblau will join SBG as Global Head of Communications, effective August 16. Mr. Kornblau joins SBG from the NBCUniversal News Group, where he is currently Executive Vice President of Communications.
Mr. Kornblau will be based in SoftBank's New York office and will report to Masayoshi Son, Representative Director, Corporate Officer, Chairman & CEO of SBG, and Marcelo Claure, Corporate Officer, Executive Vice President & COO of SBG and Chief Executive Officer of SoftBank Group International. In this role, Mr. Kornblau will be responsible for leading SBG's corporate communications strategy, directing the Company's external and internal global communications functions. He will also work with SBG's nearly 300 portfolio companies to foster alignment and value creation across the SoftBank Group ecosystem.
“Mark is a highly regarded and talented communications leader who has been a trusted advisor to CEOs, presidential candidates, government leaders and journalists for more than two decades,” said Mr. Claure. “He will be a valuable partner to our leadership team and the entrepreneurs and companies we invest in.”
Mr. Kornblau said, “SoftBank is at the center of a transformative global moment. It is shaping the future by identifying truly innovative technologies and accelerating the growth of companies that are revolutionizing the way we live and work – for the better. I’m looking forward to supporting that mission.”
At the NBCUniversal News Group, Mr. Kornblau leads communications for the award-winning portfolio of television and digital news brands and positioned the business for success in a rapidly changing media landscape. In this role, Mr. Kornblau partners with business and editorial leaders at the flagship brands of NBC News, MSNBC, TODAY, Nightly News, Meet the Press and their streaming networks and digital platforms. He also led negotiations to secure the network’s 2020 presidential primary debates, which set viewership records.
Prior to his role at NBCUniversal News Group, Mr. Kornblau was Managing Director of Corporate Communications for JPMorgan Chase, where he worked with the executive leadership team on strategic and crisis communications and oversaw media relations in support of the firm's government relations and corporate responsibility efforts.
Previously, Mr. Kornblau served in the Obama Administration as Communications Director and Spokesman for Ambassador Susan Rice at the United States Mission to the United Nations. He has held senior communications roles on two U.S. presidential campaigns, on Capitol Hill and on U.S. House and Senate campaigns.
Mr. Kornblau serves on the Board of Directors for the Careers in Culinary Arts Program, a workforce development non-profit. He received a Bachelor of Arts degree from the University of Wisconsin-Madison.
About SoftBank Group
The SoftBank Group invests in breakthrough technology to improve the quality of life for people around the world. The SoftBank Group is comprised of SoftBank Group Corp. (TOKYO: 9984), an investment holding company that includes stakes in telecommunications, internet services, AI, smart robotics, IoT and clean energy technology providers; the SoftBank Vision Funds, which are investing more than US$100 billion to help extraordinary entrepreneurs transform industries and shape new ones; the $US5 billion SoftBank Latin America Fund, the largest venture fund in that region, and the SB Opportunity Fund, a US$100 million fund dedicated to investing in enterprises founded by entrepreneurs of color in the U.S. To learn more, please visit https://global.softbank .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210707005434/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom